Genelux (GNLX) Return on Capital Employed (2023 - 2026)
Genelux's (GNLX) quarterly Return on Capital Employed came in at 187.59% in Q1 2026, up 10.86% quarter-over-quarter from 210.45% in Q4 2025.
Genelux (GNLX) Return on Capital Employed (2023 - 2026) Analysis & Trends
Genelux's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 187.59% for Q1 2026.
- On a quarterly basis, Return on Capital Employed changed N/A year-over-year to 187.59% in Q1 2026; TTM through Mar 2026 was 187.59%, a N/A change from a year earlier, with the FY2025 full-year figure at 160.87%, down 3098.0% from the prior year.
- Return on Capital Employed advanced to 187.59% in Q1 2026 per GNLX's latest filing, from 210.45% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 77.88% in Q3 2024 and bottomed at 210.45% in Q4 2025.
- The 4-year median for Return on Capital Employed is 121.66% (2024), against an average of 131.85%.
- Across the five-year window, Return on Capital Employed sank 469 bps in 2024 and plunged 10684 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 98.92% in 2023, then decreased by 5 bps to 103.62% in 2024, then plunged by 103 bps to 210.45% in 2025, then gained by 11 bps to 187.59% in 2026.
- Per Business Quant, the three latest GNLX Return on Capital Employed figures stand at 187.59% (Q1 2026), 210.45% (Q4 2025), and 142.82% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | -187.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -187.59% |
| Dec 31, 2025 | -210.45% |
| Sep 30, 2025 | -142.82% |
| Dec 31, 2024 | -103.62% |
| Sep 30, 2024 | -77.88% |
| Jun 30, 2024 | -93.79% |
| Mar 31, 2024 | -139.71% |
| Dec 31, 2023 | -98.92% |